中国肿瘤生物治疗杂志2013，Vol.20Issue(4)：383-390,8.DOI:10.3872/j.issn.1007-385X.2013.04.001
基于嵌合抗原受体修饰T细胞的肿瘤免疫治疗新策略
New strategy of tumor immunotherapy based on chimeric antigen receptor engineered T cells
摘要
Abstract
Chimeric antigen receptor (CAR)-engineered T cell is a newly developed strategy of adoptive immunotherapy.Its unique theoretical superiority and attractive application prospects open up a promising arena for anticancer therapy.CAR combines single chain variable fragment (scFv) antibody recognizing tumor-associated antigen with T cell activation motif,which endows T cells with tumor-orientated targeting ability,stronger killing activity,and prolonged survival by genetic modification.Since first proposed by Dr.Eshhar in 1989,CAR has been developed from the first generation to the second and the third generations containing costimulatory molecular.The clinical trials in leukemia,lymphoma,and melanoma have obtained exciting results.However,the off-target effect,cytokine strom,and graft-versus-host disease are potential challenges for clinical use.Future research will focus on designing safer CAR of the fourth generation,selecting good therapeutic T cell subsets,optimizing clinical scheme of administration,and improving pre-clinical models.It is believed that the obstacles from bench to clinic will be cleared and that CAR will become one of the main cancer therapies with breakthroughs in immunology,gene therapy and cell engineering.关键词
嵌合抗原受体/过继免疫治疗/肿瘤靶向治疗Key words
chimeric antigen receptor/ adoptive immunotherapy/ tumor target therapy分类
医药卫生引用本文复制引用
王艺,赵颖颖,韩双印..基于嵌合抗原受体修饰T细胞的肿瘤免疫治疗新策略[J].中国肿瘤生物治疗杂志,2013,20(4):383-390,8.基金项目
国家自然科学基金资助项目(No.81172415,No.81241077) （No.81172415,No.81241077）
河南省重点科技攻关项目资助(No.102102310065).Project supported by the National Natural Science Foundation of China(No.81172415,No.81241077),and the Key Scientific and Technological Project of Henan Province (No.102102310065) （No.102102310065）
